Votrient Related Clinical Trials
Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors [Recruiting]
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer [Recruiting]
A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors [Recruiting]
Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer [Recruiting]
VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK [Recruiting]
Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma [Recruiting]
Pazopanib and Vinflunine in Urothelial Cancer of the Bladder [Not yet recruiting]
Treatment With Pazopanib for Neoadjuvant Breast Cancer [Recruiting]
Pazopanib, Docetaxel, Prednisone Prostate [Recruiting]
Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II) [Recruiting]
Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer [Recruiting]
Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade [Recruiting]
Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible [Not yet recruiting]
Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue Sarcoma [Not yet recruiting]
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) [Recruiting]
First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma [Recruiting]
Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors [Recruiting]
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients [Recruiting]
Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST) [Recruiting]
Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors [Not yet recruiting]
GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line [Recruiting]
Pazopanib in Second-line Therapy in Renal Cell Carcinoma [Not yet recruiting]
Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma [Recruiting]
Study To Assess Long Term Safety Of Pazopanib [Recruiting]
Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma [Recruiting]
Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer [Recruiting]
Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors [Recruiting]
Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG Criteria [Not yet recruiting]
Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma [Recruiting]
HYPAZ: Hypertension Induced by Pazopanib [Recruiting]
A Phase I/II Study of Pazopanib (GW786034) and Cyclophosphamide in Patients With Platinum-resistant Recurrent, Pre-treated Ovarian Cancer [Recruiting]
Phase I Study of Pazopanib and Vorinostat [Recruiting]
Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma [Recruiting]
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer [Recruiting]
Rotating Pazopanib and Everolimus to Avoid Resistance [Recruiting]
Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery [Recruiting]
Pazopanib and ARQ 197 for Advanced Solid Tumors [Recruiting]
Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery [Recruiting]
A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors [Recruiting]
Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer [Recruiting]
Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery [Recruiting]
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors [Recruiting]
Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer [Recruiting]
Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer [Not yet recruiting]
Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors. [Recruiting]
Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma [Recruiting]
Randomized, Double-Blind, Erlotinib/ Pazopanib or Erlotinib/ Placebo, Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer(NSCLC) [Recruiting]
|
